Generation/NN
of/IN
cytotoxic/JJ
T/NN
lymphocytes/NNS
against/IN
immunorecessive/JJ
epitopes/NNS
after/IN
multiple/JJ
immunizations/NNS
with/IN
adenovirus/NN
vectors/NNS
is/VBZ
dependent/JJ
on/IN
haplotype/NN
./.

Currently/RB
,/,
adenovirus/NN
(/(
Ad/NN
)/)
is/VBZ
being/VBG
considered/VBN
as/IN
a/DT
vector/NN
for/IN
the/DT
treatment/NN
of/IN
cystic/JJ
fibrosis/NN
as/RB
well/RB
as/IN
other/JJ
diseases/NNS
./.
=====
However/RB
,/,
the/DT
cytotoxic/JJ
T/NN
lymphocyte/NN
(/(
CTL/NN
)/)
response/NN
to/TO
Ad/NN
could/MD
limit/VB
the/DT
effectiveness/NN
of/IN
such/JJ
approaches/NNS
./.
=====
Since/IN
the/DT
CTL/NN
response/NN
to/TO
virus/NN
infection/NN
is/VBZ
often/RB
focused/VBN
on/IN
one/CD
or/CC
a/DT
few/JJ
immunodominant/JJ
epitopes/NNS
,/,
one/CD
approach/NN
to/TO
circumvent/VB
this/DT
response/NN
is/VBZ
to/TO
create/VB
vectors/NNS
that/WDT
lack/VBP
these/DT
immunodominant/JJ
epitopes/NNS
./.
=====
The/DT
effectiveness/NN
of/IN
this/DT
approach/NN
was/VBD
tested/VBN
by/IN
immunizing/VBG
mice/NNS
with/IN
human/JJ
group/NN
C/NN
adenoviruses/NNS
./.
=====
Three/CD
mouse/NN
strains/NNS
(/(
C57BL/10SnJ/NN
[/(
H-2b/NN
]/)
,/,
C3HeB/FeJ/NN
[/(
H-2k/NN
]/)
,/,
and/CC
BALB/cByJ/NN
[/(
H-2d/NN
]/)
)/)
were/VBD
immunized/VBN
with/IN
wild-type/JJ
Ad/NN
or/CC
Ad/NN
vectors/NNS
lacking/VBG
the/DT
immunodominant/JJ
antigen/NN
(/(
s/NNS
)/)
,/,
and/CC
the/DT
CTL/NN
responses/NNS
were/VBD
measured/VBN
./.
=====
In/IN
C57BL/10/NN
(/(
B10/NN
)/)
mice/NNS
,/,
a/DT
single/JJ
inoculation/NN
intraperitoneally/RB
(/(
i.p./RB
)/)
led/VBD
to/TO
the/DT
recognition/NN
of/IN
an/DT
immunodominant/JJ
antigen/NN
in/IN
E1A/NN
./.
=====
When/WRB
B10/NN
mice/NNS
were/VBD
inoculated/VBN
multiple/JJ
times/NNS
either/CC
i.p./RB
=====
or/CC
intranasally/RB
with/IN
wild-type/JJ
Ad/NN
or/CC
an/DT
Ad/NN
vector/NN
lacking/VBG
most/JJS
of/IN
the/DT
E1/NN
region/NN
,/,
subdominant/JJ
epitopes/NNS
outside/IN
this/DT
region/NN
were/VBD
recognized/VBN
./.
=====
In/IN
contrast/NN
,/,
C3H/NN
mice/NNS
inoculated/VBN
with/IN
wild-type/JJ
Ad/NN
recognized/VBD
an/DT
epitope/NN
mapping/VBG
within/IN
E1B/NN
./.
When/WRB
inoculated/VBN
twice/RB
with/IN
Ad/NN
vectors/NNS
lacking/VBG
both/CC
E1A/NN
and/CC
E1B/NN
,/,
no/DT
immunorecessive/JJ
epitopes/NNS
were/VBD
recognized/VBN
./.
=====
The/DT
immune/JJ
response/NN
to/TO
Ad/NN
in/IN
BALB/c/NN
mice/NNS
was/VBD
more/RBR
complex/JJ
./.
=====
CTLs/NNS
from/IN
BALB/c/NN
mice/NNS
inoculated/VBN
i.p./RB
with/IN
wild-type/JJ
Ad/NN
recognized/VBD
E1B/NN
in/IN
the/DT
context/NN
of/IN
the/DT
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
class/NN
I/CD
Dd/NN
allele/NN
and/CC
a/DT
region/NN
outside/IN
E1/NN
associated/VBD
with/IN
the/DT
Kd/NN
allele/NN
./.
=====
When/WRB
BALB/c/NN
mice/NNS
were/VBD
inoculated/VBN
with/IN
E1-deleted/JJ
Ad/NN
vectors/NNS
,/,
only/RB
the/DT
immunodominant/JJ
Kd-restricted/JJ
epitope/NN
was/VBD
recognized/VBN
,/,
and/CC
Dd-restricted/JJ
CTLs/NNS
did/VBD
not/RB
develop/VB
./.
=====
This/DT
report/NN
indicates/VBZ
that/IN
the/DT
emergence/NN
of/IN
CTLs/NNS
against/IN
immunorecessive/JJ
epitopes/NNS
following/VBG
multiple/JJ
administrations/NNS
of/IN
Ad/NN
vectors/NNS
lacking/VBG
immunodominant/JJ
antigens/NNS
is/VBZ
dependent/JJ
on/IN
haplotype/NN
and/CC
could/MD
present/VB
an/DT
obstacle/NN
to/TO
gene/NN
therapy/NN
in/IN
an/DT
MHC-diverse/JJ
human/JJ
population/NN
./.